A Phase 3 interventional study of KarXT and KarX-EC in Alzheimer Disease and Psychosis, sponsored by Bristol-Myers Squibb. Recruiting at 22 sites in 5 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing xanomeline in Alzheimer Disease — 10 open to participants now, 10 under way, 10 of them phase 3. xanomeline · Alzheimer Disease.
Among the 10 studies testing xanomeline in Alzheimer Disease, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 10 in phase 3, and was the 6th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →10 of the 10 studies testing xanomeline in Alzheimer Disease are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Brazil and 23 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 14 more countries
Ages 60–85
Bristol-Myers Squibb · Sites in United States, Argentina, Chile and 11 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 16 more countries
Ages 60–85
Bristol-Myers Squibb · Sites in United States, Argentina, Brazil and 12 more countries
Ages 55–90
By country, each count listing its studies:
xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 325 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 463 across the 10 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
26 studies in Alzheimer Disease by Bristol-Myers Squibb: 12 open now, 13 under way, 10 of them phase 3. Of 13 finished, 0 (0%) have results posted.
Among the 26 studies in Alzheimer Disease by Bristol-Myers Squibb, this one is the 10th largest by planned enrollment, is one of 2 that started in 2026, is one of 10 in phase 3, reaches primary completion later than 7 of the 12 other live ones, and was the 21st registered.
Bristol-Myers Squibb’s Alzheimer Disease studies by the year they started, since 2007.
3 of the studies testing xanomeline in Alzheimer Disease that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies testing xanomeline in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 26 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: KarXT + KarX-EC Arm Matching Placebo
Drug: KarXT · Drug: KarX-EC
Drug pages: Xanomeline · Trospium
Specified dose on specified days
Also known as: BMS-986510, Xanomeline/Trospium Chloride
Specified dose on specified days
Also known as: BMS-986519, Xanomeline Enteric-coated
Specified dose on specified days
Change From Baseline in Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) Score
Time frame: Up to approximately Week 14
Change From Baseline in Clinical Global Impressions-Severity (CGI-S) Score
Time frame: Up to approximately Week 14
Change From Baseline in Neuropsychiatric Inventory-Clinician Rating Scale (NPI-C) Core Score
NPI-C Core Score includes assessment for hallucinations, delusions, agitation, and aggression domains
Time frame: Up to approximately Week 14
Change From Baseline in NPI-C: Agitation Score
Time frame: Up to approximately Week 14
Change From Baseline in NPI-C Core Score: Caregiver Distress Scale
NPI-C Core Score: Caregiver Distress Scale includes assessment for hallucinations, delusions, agitation, and aggression domains
Time frame: Up to approximately Week 14
Responder Rate
Responder rate is defined as improvement from baseline in NPI-C: H+D score ≥ 40%.
Time frame: Up to approximately Week 14
Change From Baseline in Cohen-Mansfield Agitation Inventory International Psychogeriatric Association (CMAI-IPA) Score
Time frame: Up to approximately Week 14
Change From Baseline in CMAI Total Score
Time frame: Up to approximately Week 14
Number of Participants With Adverse Events (AEs)
Time frame: Up to approximately Week 14
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to approximately Week 14
Number of Participants With Serious Adverse Events (SAEs)
Time frame: Up to approximately Week 14
Number of Participants With TEAEs Leading to Discontinuation
Time frame: Up to approximately Week 14
Number of Participants With Spontaneously Reported Procholinergic Symptoms
Procholinergic symptoms include nausea, vomiting, and diarrhea.
Time frame: Up to approximately Week 14
Number of Participants With Spontaneously Reported Anticholinergic Symptoms
Anticholinergic symptoms include dry mouth, constipation, urinary retention and blurred vision.
Time frame: Up to approximately Week 14
Number of Participants With AEs of Special Interest (AESIs)
AESIs such as symptomatic orthostasis, syncope, urinary adverse events, and elevated liver enzymes will be evaluated.
Time frame: Up to approximately Week 14
Barnes Akathisia Rating Scale (BARS) Score
Time frame: Up to approximately Week 14
Abnormal Involuntary Movement Scale (AIMS) Score
Time frame: Up to approximately Week 14
International Prostate Symptom Score (IPSS)
This will be measured in males only.
Time frame: Up to approximately Week 14
Body Weight
Time frame: Up to approximately Week 14
Body Mass Index (BMI)
Time frame: Up to approximately Week 14
Number of Participants With Clinically Significant Changes in Orthostatic Vital Sign: Blood Pressure (BP)
This includes measuring of BP, supine or sitting and then standing after approximately 2 minutes, no later than approximately 3 minutes.
Time frame: Up to approximately Week 14
Number of Participants With Clinically Significant Changes in Orthostatic Vital Sign: Heart Rate (HR)
This includes measuring of HR, supine or sitting and then standing after approximately 2 minutes, no later than approximately 3 minutes.
Time frame: Up to approximately Week 14
Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Hematology
Time frame: Up to approximately Week 14
Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Clinical Chemistry
Time frame: Up to approximately Week 14
Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Coagulation Parameters
Time frame: Up to approximately Week 14
Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Prolactin Levels
Time frame: Up to approximately Week 14
Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Urinalysis
Time frame: Up to approximately Week 14
Number of Participants With Clinically Significant Changes in Laboratory Evaluations: Drug Screening
Time frame: Up to approximately Week 14
Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG)
Time frame: Up to approximately Week 14
Number of Participants With Suicidal Ideations and Behavior as Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to approximately Week 14
Number of Participants With Cognitive Impairment as Assessed by Mini-mental State Examination (MMSE)
Time frame: Up to approximately Week 14
Number of Participants With Cognitive Impairment as Assessed by 13-item Variation of ADAS-Cog Scale (ADAS-Cog-13)
Time frame: Up to approximately Week 14
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Mar 2026 (actual). Primary completion is estimated for Feb 2028, 22 months after the start.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 22 months is below that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium